Titre du document / Document title

Efficacy of folic acid and enalapril combined therapy on reduction of blood pressure and plasma glucose : A multicenter, randomized, double-blind, parallel-controlled, clinical trial

Auteur(s) / Author(s)

entire study group
GUANGYUN MAO ⁽¹⁾ ; XIUMEI HONG ⁽²⁾ ; HOUXUN XING ⁽¹⁾ ; PING LIU ⁽¹⁾ ; HAIPENG LIU ⁽³⁾ ; YUNXIAN YU ⁽²⁾ ; SHANCHUN ZHANG ⁽²⁾ ; SHANQUN JIANG ⁽¹⁾ ; XIAOBIN WANG ⁽²⁾ ; XIPING XU ^{(1 4)} ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Anhui Biomedical Institute, Anhui Medical University, Hefei, CHINE
⁽²⁾ Mary Ann and J. Milburn Smith Child Health Research Program, Children's Memorial Hospital and Children's Memorial Research Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, ETATS-UNIS
⁽³⁾ School of Life Science, University of Science and Technology of China, Hefei, CHINE
⁽⁴⁾ Division of Epidemiology and Biostatistics, University of Illinois at Chicago School of Public Health, Chicago, Illinois, ETATS-UNIS

Résumé / Abstract

Objective: We compared the efficacy of folic acid (FA) plus enalapril with enalapril alone on the reduction of blood pressure (BP) and fasting plasma glucose (FPG) in adult Chinese hypertensive patients. Methods: Four hundred eighty subjects with mild to moderate BP were randomly assigned to one of three treatment groups: 1) 10 mg of enalapril (control group), 2) 10 mg of enalapril plus 0.4 mg of FA (low-FA group), or 3) 10 mg of enalapril plus 0.8 mg of FA (high-FA group) daily for 8 wk. Generalized linear mixed models were used to compare the reduction in BP and FPG level from baseline to week 8 of the treatment and the difference among the three treatment groups, adjusting for pertinent covariates. Results: Four hundred forty-three subjects (57.3% women, 27-75 y of age) successfully completed the trial. After the 8-wk treatment, compared with baseline, all treatment groups showed significant reduction of BP but not of FPG. There was no significant difference in BP or FPG reduction among the three treatment groups. In subgroup analysis, we found that in subjects with hyperglycemia (FPG ≥6.1 mmol/L) at baseline, FPG reduction was significantly greater in the high-FA group (-0.80 ± 1.20 mmol/L) than in the low-FA group (- 0.39 ± 1.44 mmol/L) and the control group (- 0.23 ± 1.30 mmol/L). Regression analysis further confirmed that FPG reduction in the high-FA group was -0.68 ± 0.28 mmol/L greater than in the control group (P = 0.015), even after adjustment for important covariates. A dose-response trend was evident (P for trend = 0.025) and the test for an interaction between treatment group and baseline FPG was significant (P < 0.001). Conclusion: In this sample of adult Chinese hypertensive patients, FA combined with enalapril showed a greater beneficial effect on reduction of FPG in a dose-related fashion than did enalapril alone among subjects with hyperglycemia.

Revue / Journal Title

Nutrition   ISSN 0899-9007   CODEN NUTRER 

Source / Source

2008, vol. 24, n^o11-12, pp. 1088-1096 [9 page(s) (article)] (35 ref.)

Langue / Language

Anglais

Editeur / Publisher

Elsevier, New York, NY, ETATS-UNIS  (1987) (Revue)

Mots-clés anglais / English Keywords

Cardiovascular disease ; Hemodynamics ; Vertebrata ; Mammalia ; Chinese ; Hypertension ; Hyperglycemia ; Clinical trial ; Double blind study ; Glucose ; Blood pressure ; Blood plasma ; Combined treatment ; Folic acid ;

Mots-clés français / French Keywords

Pathologie de l'appareil circulatoire ; Hémodynamique ; Vertebrata ; Mammalia ; Chinois ; Hypertension artérielle ; Hyperglycémie ; Essai clinique ; Etude double insu ; Glucose ; Pression sanguine ; Plasma sanguin ; Traitement associé ; Acide folique ;

Mots-clés espagnols / Spanish Keywords

Aparato circulatorio patología ; Hemodinámica ; Vertebrata ; Mammalia ; Chino ; Hipertensión arterial ; Hiperglicemia ; Ensayo clínico ; Estudio doble ciego ; Glucosa ; Presión sanguínea ; Plasma sanguíneo ; Tratamiento asociado ; Acido fólico ;

Mots-clés d'auteur / Author Keywords

Enalapril ; Folic acid ; Hyperglycemia ; Hypertension ; Randomized clinical trial ; Chinese ;

Localisation / Location

INIST-CNRS, Cote INIST : 22165, 35400018444514.0050